bioaccess® LATAM CRO EPERTS

At bioaccess®, we empower Medtech and Biopharma innovators to accelerate breakthroughs with global-first clinical agility. By combining Latin America’s regulatory speed, Eastern Europe's diverse patient pools, and Australia’s streamlined pathways, we deliver ethical approvals in 4–6 weeks and enrollment 50% faster than traditional markets. Why Choose Us? -Speed Without Compromise: Ethics approvals in 4–6 weeks (vs. 6–12 months in US/EU) via partnerships with regulatory agencies. -Cost Efficiency: 30% lower operational costs through pre-negotiated site contracts and favorable regional exchange rates. -Global Compliance: 100% ICH-GCP alignment ensures FDA/EMA-ready datasets – no rework, no delays. -Regional Edge: Latin America: 50+ sites across Colombia, Brazil, and Mexico for cardiology, orthopedics, and neurology trials. Balkans: Accelerated parallel reviews in Serbia (80-day approvals) and access to rare disease populations in Kosovo. Australia: TGA CTN pathways for low-risk devices, bridging Phase I trials to US IND submissions.